- Conditions
- Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
- Interventions
- Atezolizumab, Biospecimen Collection, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
- Drug · Procedure · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 391
- States / cities
- Anchorage, Alaska • Jonesboro, Arkansas • Little Rock, Arkansas + 291 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 356
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Pain
- Interventions
- [18F]FDG, PET/MRI
- Drug · Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2022
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Glioblastoma, Glioblastoma, IDH-Wildtype, Gliosarcoma, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Resectable Glioblastoma
- Interventions
- Biospecimen Collection, Echocardiography Test, EGFR Inhibitor ERAS-801, Fludeoxyglucose F-18, Magnetic Resonance Imaging, Positron Emission Tomography, Surgical Procedure
- Procedure · Drug · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Los Angeles, California • New York, New York
- Conditions
- Breast Cancer
- Interventions
- [18F]Flutemetamol, [18F]fluoro-2-deoxy-D-glucose (FDG), Functional Magnetic Resonance Imaging (fMRI)
- Drug · Diagnostic Test
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Alzheimer's Disease
- Interventions
- AZD0530 100mg daily, AZD0530 125mg daily, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Los Angeles, California + 17 more
- Conditions
- Cardiac Sarcoidosis
- Interventions
- hybrid PET/MRI
- Diagnostic Test
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Painful Joint Prostheses
- Interventions
- FDG-PET Imaging
- Procedure
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Osimertinib, Tegavivint, Echocardiography Test, Multigated Acquisition Scan, Computed Tomography, FDG-Positron Emission Tomography, Biospecimen Collection
- Drug · Procedure
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Cervical Cancer
- Interventions
- fludeoxyglucose F 18, fluorine F 18 EF5
- Radiation
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Lymphoma
- Interventions
- Fludeoxyglucose F18, Computed Tomography, Positron emission tomography
- Radiation · Procedure
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Patellofemoral Osteoarthritis, Knee Osteoarthritis, Knee Pain, Inflamation
- Interventions
- Not listed
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Cancer
- Interventions
- PET scanning in cancer
- Other
- Lead sponsor
- American College of Radiology Imaging Network
- Network
- Eligibility
- Not listed
- Enrollment
- 333,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer, Stage IVB Follicular Thyroid Cancer, Stage IVB Papillary Thyroid Cancer, Stage IVC Follicular Thyroid Cancer, Stage IVC Papillary Thyroid Cancer
- Interventions
- Decitabine, Iodine I 131, Recombinant thyrotropin alfa, Fludeoxyglucose F 18, Positron emission tomography
- Drug · Radiation · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2014
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Columbus, Ohio • Houston, Texas
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Interventions
- Computed Tomography, Fludeoxyglucose F-18, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Positron Emission Tomography, Sodium Fluoride F-18
- Procedure · Other · Radiation + 1 more
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Lung Inflammation
- Interventions
- Zileuton, Pioglitazone placebo, Zileuton placebo, Pioglitazone
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 19 Years to 44 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Alzheimer's Disease, Lewy Body Dementia, Parkinson's Disease
- Interventions
- DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, Clinical Assessment
- Radiation · Genetic · Procedure + 1 more
- Lead sponsor
- Douglas Scharre
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Multiple Myeloma (MM)
- Interventions
- PET-enabled dual-energy CT imaging, X-ray dual-energy CT imaging
- Diagnostic Test
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Esophageal Cancer
- Interventions
- conventional surgery, positron emission tomography, radionuclide imaging, fludeoxyglucose F 18, chemotherapy, Radiotherapy
- Procedure · Radiation · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 235 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2009
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 26 more
- Conditions
- Erdheim-Chester Disease, Langerhans Cell Histiocytosis, Histiocytic Disorders
- Interventions
- F-choline PET Scan, FDG-PET, biopsy
- Radiation · Device · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- B-Cell Neoplasm, Estrogen Receptor Negative, HER2/Neu Negative, Metastatic Renal Cell Cancer, Progesterone Receptor Negative, Stage III Mesothelioma, Stage III Renal Cell Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Mesothelioma, Stage IV Non-Small Cell Lung Cancer, Stage IV Renal Cell Cancer, Triple-Negative Breast Carcinoma
- Interventions
- 18F-FSPG, 18F-FDG
- Drug
- Lead sponsor
- Andrei Iagaru
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Recurrent Thyroid Gland Carcinoma, Stage III Thyroid Gland Follicular Carcinoma, Stage III Thyroid Gland Papillary Carcinoma, Stage IV Thyroid Gland Follicular Carcinoma, Stage IV Thyroid Gland Papillary Carcinoma
- Interventions
- Fludeoxyglucose F-18, Laboratory Biomarker Analysis, Pharmacological Study, Positron Emission Tomography, Ziv-Aflibercept
- Radiation · Other · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- EGFR Gene Amplification, EGFR Gene Mutation, Glioblastoma, Recurrent Glioblastoma, Supratentorial Glioblastoma, TP53 Wt Allele
- Interventions
- Fludeoxyglucose F-18, Osimertinib, Positron Emission Tomography
- Other · Drug · Procedure
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Venothromboembolism
- Interventions
- FDG-PET/CT
- Procedure
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Interventions
- aflibercept, oxaliplatin, leucovorin, fluorouracil, Correlative Studies, DCE MRI, f18FDG-PET, PET (positron emission tomography)
- Biological · Drug · Other + 2 more
- Lead sponsor
- John Hays
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 6
- States / cities
- Ann Arbor, Michigan • Buffalo, New York • The Bronx, New York + 3 more